rpn-6.1 Antibody

What is RPN-6.1 and what is its function in the proteasome complex?

RPN-6.1 serves as an essential structural component that facilitates the association of the 19S regulatory particle with the 20S core particle in the 26S proteasome. This complex is the major enzymatic machinery necessary for ubiquitin-dependent protein degradation in eukaryotic cells. Unlike catalytic components, RPN-6.1 has no enzymatic activity but instead acts as a molecular clamp that helps maintain proteasome assembly and structural integrity.

What antibodies are currently available for RPN-6.1 detection?

Several antibodies are available for RPN-6.1 detection, with varying specifications and applications:

When selecting an antibody, consider the specific experimental requirements, including species reactivity, application compatibility, and epitope recognition. For C. elegans studies, antibodies with confirmed invertebrate reactivity are essential, such as the commercially available rabbit polyclonal antibodies.

What is the typical subcellular localization of RPN-6.1?

RPN-6.1 displays a complex localization pattern that includes both nuclear and cytoplasmic distribution. Immunostaining studies of RPN-6.1::OLLAS animals with anti-OLLAS antibodies reveal staining in both the nuclei and cytoplasm of cells, though with tissue-specific expression patterns.

Particularly in C. elegans germline cells, RPN-6.1 shows distinct localization patterns that are crucial for its function. Proper localization of RPN-6.1 is essential for the nuclear positioning of other 19S RP lid subunits, including RPN-8 and RPN-9. This suggests that RPN-6.1 may serve as a critical spatial organizer for proteasome assembly in specific cellular compartments.

The localization pattern can also change in response to cellular stressors, aging, or experimental manipulations of the proteasome, making it a potential marker for proteasomal stress responses.

How can I generate RPN-6.1 tagged strains using CRISPR/Cas9?

CRISPR/Cas9 genome editing offers precise tagging of endogenous RPN-6.1. Here is a methodological approach for C. elegans:

For C-terminal OLLAS-tagging:

• Design a crRNA targeting a site adjacent to the stop codon of rpn-6.1

• Prepare an ssODN repair template containing:

  • 35bp homology arms flanking the insertion site

  • The 42bp OLLAS sequence (5'-tccggattcgccaacgagctcggaccacgtctcatgggaaag-3')

  • Silent mutations to prevent recutting by the crRNA

• Use the Co-CRISPR method with unc-58 or dpy-10 as co-CRISPR markers

• Screen for edits by PCR followed by SacI digestion (the OLLAS sequence contains a SacI site)

• Confirm successful edits by sequencing

• Backcross with wild-type (N2) strains at least 5 times

For N-terminal GFP tagging:

• Design a crRNA targeting a site near the start codon

• Prepare a repair template with Superfolder GFP sequence

• Include appropriate homology arms and silent mutations

• Follow similar screening and validation procedures as above

This approach has successfully generated functional tagged RPN-6.1 strains that maintain normal proteasome activity while allowing visualization and immunoprecipitation studies.

What are the effects of RPN-6.1 knockdown on proteasome function and cellular processes?

RPN-6.1 knockdown produces significant and specific effects on proteasomal function and cellular processes:

• Impaired proteasome assembly: Depletion disrupts the association between the 19S regulatory particle and 20S core particle

• Altered subcellular localization: RPN-6.1 knockdown prevents proper nuclear localization of 19S RP lid subcomplexes, particularly affecting RPN-8 and RPN-9

• Protein accumulation: Causes increased levels of proteins normally degraded by the proteasome, such as GSP-1 and GSP-2, in both cytoplasm and nucleus

• Lifespan effects: Prevents life span extension mediated by XPO-1 (Exportin 1) silencing, indicating a critical role in longevity pathways

• Nucleolar dynamics: Affects nucleolar size regulation, potentially through impacts on ribosomal protein surveillance

Unlike some other proteasome subunits (e.g., RPN-10), RPN-6.1 knockdown doesn't cause sexual transformation in C. elegans hermaphrodites, suggesting specialized rather than general developmental functions.

How does RPN-6.1 contribute to lifespan regulation and proteostasis?

RPN-6.1 plays a significant role in lifespan regulation through several interconnected mechanisms:

• Enhanced proteolytic capacity: Overexpression of RPN-6.1 increases proteasome activity, promoting efficient clearance of damaged or misfolded proteins that accumulate during aging

• Requirement in longevity pathways: RPN-6.1 is specifically required for lifespan extension mediated by XPO-1 (Exportin 1) silencing

• Nucleolar regulation: RPN-6.1 contributes to nucleolar size control, which is linked to longevity in C. elegans

• Pathway specificity: Unlike treatment with 5-fluorodeoxyuridine (FUdR), which enhances proteasome function independently of RPN-6.1, some longevity pathways specifically require RPN-6.1 function

The emerging model suggests that RPN-6.1 serves as a critical node in proteostasis networks that maintain cellular health during aging by ensuring efficient protein quality control. Its upregulation appears to be an adaptive response that promotes longevity by preventing the accumulation of proteotoxic species.

What methods are available for studying RPN-6.1-mediated protein degradation?

Several complementary approaches can be used to investigate RPN-6.1's role in protein degradation:

How can I validate the specificity of RPN-6.1 antibodies?

Thorough validation is critical for ensuring antibody specificity. Follow these methodological approaches:

• Genetic controls:

  • Test antibody reactivity in RPN-6.1 knockdown/knockout samples

  • Compare staining patterns in wild-type versus RPN-6.1 depleted samples

  • Use RPN-6.1 overexpression as a positive control

• Peptide competition assays:

  • Pre-incubate antibody with the immunizing peptide or recombinant RPN-6.1

  • Compare staining with and without competition

  • Specific signals should be blocked by the competing peptide

• Cross-reactivity testing:

  • Test against samples from multiple species to confirm expected reactivity

  • Examine reactivity against related proteasome subunits

  • Verify absence of signal in non-expressing tissues or cells

• Tagged protein controls:

  • Compare antibody staining with direct visualization of GFP::RPN-6.1 or RPN-6.1::OLLAS

  • Co-localization of signals confirms specificity

  • Absence of signal in untagged controls confirms tag specificity

• Application-specific validation:

  • For western blotting: confirm band at expected molecular weight (~47 kDa for C. elegans RPN-6.1)

  • For immunoprecipitation: verify pull-down of known interacting partners

  • For immunostaining: compare with published localization patterns

What is the relationship between RPN-6.1 and other proteasome subunits?

RPN-6.1 maintains complex relationships with other proteasome subunits that extend beyond structural association:

• Assembly regulation: RPN-6.1, together with RPN-7, is required for the nuclear localization of the 19S RP lid particle subcomplexes

• Hierarchical organization: Unlike proteasome subunits with specialized functions (e.g., RPN-10, RPN-12, DSS-1 in germline development), RPN-6.1 has broader roles in proteasome integrity

• Expression coordination: RPN-6.1 can regulate the production of other proteasome subunits, creating feedback loops in proteasome biogenesis

• Functional dependencies:

  • When RPN-6.1 is depleted, the localization of RPN-8 and RPN-9 is disrupted specifically in oocytes

  • This suggests tissue-specific assembly pathways dependent on RPN-6.1

• Evolutionary conservation: The relationship between RPN-6.1 and other subunits is highly conserved, with similar interactions observed between mammalian PSMD11 and its partner subunits

How can RPN-6.1 be targeted pharmacologically, and what are the effects?

Emerging research suggests RPN-6.1 may be druggable with specific phenotypic consequences:

• Available chemical probes:

  • TXS-8, a lead compound with low micromolar binding affinity for RPN-6

  • Shows limited binding to other proteins, suggesting specificity

  • Serves as a primary scaffold for designing more potent binders

• Cellular effects:

  • Cytotoxicity in various cell lines, with increased effects on hematological cancers

  • Potential disruption of 26S proteasome assembly rather than direct inhibition of catalytic sites

• Experimental applications:

  • Probe for studying RPN-6.1 functions distinct from its structural role

  • Tool for investigating cancer cell dependencies on proteasome function

  • Starting point for development of more specific modulators

• Methodological approaches:

  • Thermal shift assays to identify small molecule binders

  • One-bead, one-compound library screening approaches

  • Structure-activity relationship studies to improve potency and specificity

This emerging area suggests that RPN-6.1-targeted compounds could become valuable tools for both basic research and potential therapeutic development, particularly for malignancies dependent on elevated proteasome activity.

What role does RPN-6.1 play in nucleolar dynamics and ribosome regulation?

RPN-6.1 has unexpected connections to nucleolar function and ribosomal regulation:

• Nucleolar size regulation:

  • RPN-6.1 silencing affects nucleolar size, suggesting a role in nucleolar dynamics

  • This function may be mediated through effects on ribosomal proteins

• Interaction with ribosomal pathways:

  • RPN-6.1 is required for XPO-1 (Exportin 1)-mediated nucleolar size regulation

  • This pathway involves the nucleolar protein FIB-1 and potentially ribosomal RNA processing

• Proteolytic control:

  • RPN-6.1-dependent proteasomal activity may regulate levels of key nucleolar components

  • This creates a link between protein degradation and ribosome biogenesis

• Experimental approaches:

  • Monitor nucleolar size in RPN-6.1 knockdown or overexpression backgrounds

  • Assess rRNA levels and processing using Bioanalyzer or qPCR

  • Examine interactions with nucleolar proteins through co-localization or co-IP studies

These findings reveal an unexpected role for RPN-6.1 in coordinating proteostasis with ribosome biogenesis, two fundamental cellular processes that must be balanced for cellular homeostasis.

How does RPN-6.1 function compare between different species and model organisms?

RPN-6.1 functions show both conservation and specialization across species:

This evolutionary conservation highlights the fundamental importance of RPN-6.1 in eukaryotic proteostasis while pointing to potential species-specific adaptations that may inform translational research.

What experimental controls should I include when studying RPN-6.1?

Robust experimental design requires appropriate controls:

• For antibody-based detection:

  • Negative controls: RPN-6.1 knockdown or knockout samples

  • Specificity controls: Pre-incubation with immunizing peptide

  • Loading controls: Constitutively expressed proteins unaffected by treatments

• For genetic manipulation:

  • Empty vector controls for RNAi experiments

  • Non-targeting RNAi controls

  • Wild-type comparison strains maintained under identical conditions

  • Rescue experiments to confirm specificity of observed phenotypes

• For tagged constructs:

  • Untagged controls to assess tag-specific effects

  • Alternative tag positions (N- vs C-terminal) to confirm functionality

  • Functional validation through rescue of knockout phenotypes

• For protein interaction studies:

  • IgG controls for immunoprecipitation

  • Pulldowns from lysates lacking the bait protein

  • Reciprocal co-immunoprecipitation experiments

  • Controls for non-specific binding to beads or matrices

• For localization studies:

  • Multiple fixation and permeabilization protocols to confirm patterns

  • Comparison of antibody staining with direct visualization of tagged proteins

  • Subcellular fractionation to biochemically validate microscopy findings

How can I optimize RPN-6.1 immunostaining protocols?

Successful immunostaining of RPN-6.1 requires careful optimization:

• Fixation optimization:

  • Test multiple fixatives (4% paraformaldehyde, methanol, or combinations)

  • Adjust fixation times and temperatures

  • For C. elegans, freeze-crack methods may improve antibody accessibility

• Permeabilization:

  • Optimize detergent type and concentration (Triton X-100, Tween-20, saponin)

  • Adjust permeabilization time based on tissue type

  • Consider antigen retrieval methods if signal is weak

• Antibody conditions:

  • Titrate primary antibody concentrations (typically 1:100 to 1:1000)

  • Test different incubation times and temperatures

  • Use validated antibodies with confirmed reactivity to your species

• Signal enhancement:

  • Consider tyramide signal amplification for weak signals

  • Use high-sensitivity detection systems like Alexa Fluor conjugates

  • Optimize blocking conditions to reduce background

• Special considerations for C. elegans:

  • For dissected gonads or embryos, optimize the dissection buffer

  • When using anti-OLLAS for RPN-6.1::OLLAS detection, perform a mild post-fixation after primary antibody incubation

  • Mount in anti-fade media containing DAPI for nuclear counterstaining

This optimization process should be systematic, changing one variable at a time and documenting outcomes to establish a reliable protocol.

What approaches can I use to quantify changes in RPN-6.1 expression levels?

Accurate quantification of RPN-6.1 requires appropriate methodological approaches:

• Protein-level quantification:

  • Western blotting with RPN-6.1-specific antibodies

  • Normalization to appropriate loading controls (e.g., tubulin, actin)

  • Densitometry analysis with statistical validation

  • Consider using fluorescent secondary antibodies for wider linear range

• Transcript-level quantification:

  • RT-qPCR with validated primers for rpn-6.1

  • Normalization to stable reference genes (e.g., pmp-3 as used in study )

  • RNA-seq for genome-wide context of expression changes

• For tagged RPN-6.1:

  • Direct fluorescence intensity measurements of GFP::RPN-6.1

  • Automated image analysis of immunostained RPN-6.1::OLLAS

  • Flow cytometry if using cell culture systems

• Mass spectrometry approaches:

  • Label-free quantification from whole proteome analysis

  • SILAC or TMT labeling for precise relative quantification

  • Selected reaction monitoring (SRM) for absolute quantification

• Single-cell analysis:

  • Single-cell RNA-seq to detect cell-type-specific expression changes

  • Quantitative microscopy with cellular segmentation

  • Flow cytometry with RPN-6.1 antibodies for cell-by-cell analysis

Each method has specific advantages and limitations, so combining multiple approaches provides the most robust quantification of RPN-6.1 expression changes.

What are emerging areas of research regarding RPN-6.1?

Current literature points to several promising research frontiers:

• Therapeutic targeting:

  • Development of more specific RPN-6.1 binders based on the TXS-8 scaffold

  • Investigation of RPN-6.1 as a potential target in cancer, particularly hematological malignancies

  • Exploration of RPN-6.1 modulation in age-related diseases

• Tissue-specific functions:

  • Further characterization of RPN-6.1's tissue-specific expression and functions

  • Investigation of its specialized roles in the germline versus somatic tissues

  • Exploration of neural functions of RPN-6.1 in models of neurodegeneration

• Integration with other cellular pathways:

  • Deeper exploration of the connection between RPN-6.1 and nucleolar dynamics

  • Investigation of its role in ribosomal protein surveillance

  • Understanding links between RPN-6.1 and nuclear export/import pathways

• Aging and proteostasis:

  • Mechanisms by which RPN-6.1 overexpression extends lifespan

  • Identification of key substrates whose degradation is most affected by RPN-6.1 levels

  • Development of interventions to boost RPN-6.1 activity in aging organisms

• High-resolution structural studies:

  • Cryo-EM studies of how RPN-6.1 mediates 19S-20S association

  • Structural basis for RPN-6.1 interactions with small molecule modulators

  • Conformational changes in RPN-6.1 during proteasome assembly and activity

These emerging areas represent significant opportunities for researchers to make fundamental contributions to our understanding of proteostasis regulation.

What potential clinical applications exist for RPN-6.1 research?

Research on RPN-6.1 has several translational implications:

• Cancer therapeutics:

  • TXS-8 showed increased cytotoxicity in hematological cancers

  • This suggests potential for targeting RPN-6.1 in specific malignancies

  • Could provide an alternative approach to proteasome inhibition distinct from catalytic site inhibitors like bortezomib

• Age-related diseases:

  • Given RPN-6.1's role in lifespan regulation, it may be relevant for age-related pathologies

  • Potential applications in neurodegenerative diseases where protein aggregation is prominent

  • Possible enhancement of proteostasis in conditions like Alzheimer's or Parkinson's disease

• Diagnostic applications:

  • RPN-6.1 expression or modification patterns could serve as biomarkers

  • May indicate proteasome dysfunction in specific disease states

  • Could help identify patients likely to respond to proteasome-targeting therapies

• Screening platforms:

  • Development of high-throughput screens for RPN-6.1 modulators

  • Reporter systems based on RPN-6.1-dependent degradation pathways

  • Drug discovery platforms focused on proteostasis enhancement

As research progresses, translating these findings from model organisms to clinical applications will require careful validation in human cellular and tissue systems.